Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 6/2/2018 |
| Start Date: | August 2013 |
| End Date: | May 2018 |
PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES IN INDUCED PLURIPOTENT STEM (IPS) CELLS STUDY (PEAR-IPSC) (PEAR-iPSC)
Patients enrolled in this study will have completed one of the parent studies
"Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how
well their blood pressure was controlled by medication. Patients in the current study will
provide a single tube of blood which will be used to create adult stem cells that can be
converted into other cell types, like heart or vasculature. Patients will not be asked to
return for any follow up visits.
"Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how
well their blood pressure was controlled by medication. Patients in the current study will
provide a single tube of blood which will be used to create adult stem cells that can be
converted into other cell types, like heart or vasculature. Patients will not be asked to
return for any follow up visits.
If the patient decide to participate in this study, they will have 1 visit for the study that
will include a blood draw. Upon arrival to the clinic, the study will be explained to the
patient in detail. The patient will be asked at that time to sign this consent form. The
patient will have the opportunity to ask questions and the research staff will answer those
questions. If the patient decides to participate in this study and sign a consent form, then
a blood sample will be collected from a vein in the arm. A total of 2 teaspoons full of blood
will be drawn for the study.
During this visit, in addition to collecting a blood sample, patients will be asked about
their medical history and medications they are currently taking, and will have their vital
signs assessed, including blood pressure, pulse, and temperature.
Blood will be drawn by a trained nurse or a phlebotomist at a family medicine clinic in
Gainesville, Florida. The blood sample will be further processed in laboratories at the
University of Florida, for the establishment of iPS cells. iPS cells will retain the
patient's genetic makeup which makes them useful for research. Several experiments will be
conducted on these cells that will provide data that can be used to learn more about how
genetic markers can lead to differences in blood pressure response to medicines. These cells
will be used for up to 8 years.
will include a blood draw. Upon arrival to the clinic, the study will be explained to the
patient in detail. The patient will be asked at that time to sign this consent form. The
patient will have the opportunity to ask questions and the research staff will answer those
questions. If the patient decides to participate in this study and sign a consent form, then
a blood sample will be collected from a vein in the arm. A total of 2 teaspoons full of blood
will be drawn for the study.
During this visit, in addition to collecting a blood sample, patients will be asked about
their medical history and medications they are currently taking, and will have their vital
signs assessed, including blood pressure, pulse, and temperature.
Blood will be drawn by a trained nurse or a phlebotomist at a family medicine clinic in
Gainesville, Florida. The blood sample will be further processed in laboratories at the
University of Florida, for the establishment of iPS cells. iPS cells will retain the
patient's genetic makeup which makes them useful for research. Several experiments will be
conducted on these cells that will provide data that can be used to learn more about how
genetic markers can lead to differences in blood pressure response to medicines. These cells
will be used for up to 8 years.
Inclusion Criteria:
- participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
- assigned to a diuretic arm
Exclusion Criteria:
- no participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
- assigned to a beta blocker arm
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
